Pacific Days Sales Outstanding vs Pe Ratio Analysis
PACB Stock | USD 2.27 0.07 2.99% |
Pacific Biosciences financial indicator trend analysis is much more than just breaking down Pacific Biosciences prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Pacific Biosciences is a good investment. Please check the relationship between Pacific Biosciences Days Sales Outstanding and its Pe Ratio accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pacific Biosciences of. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
Days Sales Outstanding vs Pe Ratio
Days Sales Outstanding vs Pe Ratio Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Pacific Biosciences Days Sales Outstanding account and Pe Ratio. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Pacific Biosciences' Days Sales Outstanding and Pe Ratio is 0.42. Overlapping area represents the amount of variation of Days Sales Outstanding that can explain the historical movement of Pe Ratio in the same time period over historical financial statements of Pacific Biosciences of, assuming nothing else is changed. The correlation between historical values of Pacific Biosciences' Days Sales Outstanding and Pe Ratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Days Sales Outstanding of Pacific Biosciences of are associated (or correlated) with its Pe Ratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Pe Ratio has no effect on the direction of Days Sales Outstanding i.e., Pacific Biosciences' Days Sales Outstanding and Pe Ratio go up and down completely randomly.
Correlation Coefficient | 0.42 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Days Sales Outstanding
Pe Ratio
Most indicators from Pacific Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Pacific Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pacific Biosciences of. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. The current year's Selling General Administrative is expected to grow to about 177.3 M, whereas Tax Provision is forecasted to decline to (11.2 M).
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 58.9M | 49.0M | 52.8M | 28.1M | Total Revenue | 130.5M | 128.3M | 200.5M | 210.5M |
Pacific Biosciences fundamental ratios Correlations
Click cells to compare fundamentals
Pacific Biosciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Pacific Biosciences fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Common Stock Shares Outstanding | 152.5M | 175.0M | 204.1M | 224.6M | 253.6M | 266.3M | |
Total Assets | 148.0M | 414.0M | 2.0B | 1.8B | 1.7B | 1.8B | |
Short Long Term Debt Total | 61.7M | 42.0M | 953.7M | 957.4M | 933.9M | 980.6M | |
Other Current Liab | (13.9M) | 17.5M | 40.4M | 201.2M | 53.5M | 56.2M | |
Total Current Liabilities | 21.8M | 36.5M | 83.3M | 76.9M | 95.0M | 99.8M | |
Total Stockholder Equity | 54.9M | 335.5M | 791.0M | 562.9M | 701.3M | 736.4M | |
Other Liab | 2.0M | 10.3M | 215.0M | 2.6M | 3.0M | 2.8M | |
Property Plant And Equipment Net | 62.9M | 54.9M | 79.1M | 81.3M | 69.0M | 35.5M | |
Current Deferred Revenue | 7.6M | 10.3M | 36.0M | 32.3M | 16.3M | 13.1M | |
Net Debt | 12.6M | (276.8M) | 493.0M | 632.3M | 754.0M | 791.7M | |
Retained Earnings | (1.1B) | (1.0B) | (1.2B) | (1.5B) | (1.8B) | (1.7B) | |
Accounts Payable | 8.4M | 3.6M | 11.0M | 12.0M | 15.1M | 7.6M | |
Cash | 49.1M | 318.8M | 460.7M | 325.1M | 179.9M | 137.4M | |
Non Current Assets Total | 66.9M | 59.2M | 901.2M | 912.1M | 1.0B | 1.1B | |
Non Currrent Assets Other | 42K | 879K | 1.2M | 10.5M | 3.7M | 3.7M | |
Other Assets | 4.0M | 33.5M | 1.2M | 13.5M | 1.0 | 0.95 | |
Cash And Short Term Investments | 49.1M | 318.8M | 1.0B | 772.3M | 631.4M | 663.0M | |
Short Term Investments | 19.5M | 237.2M | 583.7M | 447.2M | 451.5M | 474.1M | |
Liabilities And Stockholders Equity | 148.0M | 414.0M | 2.0B | 1.8B | 1.7B | 1.8B | |
Non Current Liabilities Total | 71.2M | 42.0M | 1.1B | 1.1B | 949.7M | 997.2M | |
Other Current Assets | 3.4M | 5.7M | 7.9M | 10.6M | 17.3M | 18.2M | |
Other Stockholder Equity | 1.1B | 1.4B | 2.0B | 2.1B | 2.5B | 2.7B | |
Total Liab | 93.1M | 78.5M | 1.2B | 1.2B | 1.0B | 1.1B | |
Property Plant And Equipment Gross | 62.9M | 54.9M | 79.1M | 81.3M | 143.8M | 151.0M | |
Total Current Assets | 81.0M | 354.8M | 1.1B | 855.0M | 742.0M | 779.1M | |
Short Term Debt | 19.7M | 8.7M | 9.3M | 19.6M | 10.1M | 8.2M | |
Property Plant Equipment | 30.1M | 24.9M | 79.1M | 81.3M | 93.5M | 98.2M | |
Long Term Debt | 14.7M | 15.9M | 896.1M | 896.7M | 892.2M | 936.9M | |
Net Receivables | 15.3M | 16.8M | 24.2M | 18.8M | 36.6M | 38.4M | |
Common Stock Total Equity | 150K | 153K | 192K | 221K | 198.9K | 189.0K | |
Inventory | 13.3M | 14.2M | 24.6M | 50.4M | 56.7M | 59.5M | |
Common Stock | 153K | 192K | 221K | 227K | 268K | 254.6K | |
Net Tangible Assets | 54.9M | 335.5M | (30.0M) | (257.3M) | (231.6M) | (220.0M) | |
Retained Earnings Total Equity | (982.1M) | (1.1B) | (1.0B) | (1.2B) | (1.1B) | (1.2B) | |
Capital Surpluse | 1.1B | 1.1B | 1.4B | 2.0B | 2.3B | 1.2B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Pacific Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Pacific Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Pacific Biosciences Of Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Pacific Biosciences Of Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pacific Biosciences of. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pacific Biosciences. If investors know Pacific will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pacific Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.46) | Revenue Per Share 0.64 | Quarterly Revenue Growth (0.28) | Return On Assets (0.11) | Return On Equity (0.65) |
The market value of Pacific Biosciences is measured differently than its book value, which is the value of Pacific that is recorded on the company's balance sheet. Investors also form their own opinion of Pacific Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Pacific Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pacific Biosciences' market value can be influenced by many factors that don't directly affect Pacific Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pacific Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pacific Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pacific Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.